Q32 Bio Inc. Overview
Pro stress-test →Q32 Bio is a clinical-stage biotechnology company that develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program.
Strategic Profile
Pro stress-test →Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront and near-term payments, eligible for up to $592 million in total milestone payments plus tiered royalties. This transaction extends the company's cash runway into the second half of 2027 while it advances bempikibart, with SIGNAL-AA Part B topline data on track for mid-2026.
Competitive Landscape
Pro stress-test →Q32 Bio competes in the alopecia areata therapeutics space, an emerging category with limited approved treatments. The company's main focus is bempikibart for atopic dermatitis and alopecia areata, with a supporting complement platform including ADX-096 for ophthalmologic indications. Competitors include other immunology-focused biotech companies pursuing immune rebalancing approaches.
Industry Context
Q32 Bio Inc. operates in Biotechnology - Immunology & Inflammation (Biopharmaceuticals).
Key facts
Founded: 2017 · Headquarters: Waltham, Massachusetts, US · Employees: 42 · Revenue: N/A · Market cap: $52.5M